FASLG and pancreatic neoplasm: The CD95L-antagonist sCD95Fc substantially reduced cytokine (TNF-α or TRAIL)-stimulated IL-6 and IL-8 expression and generally lowered the pro-inflammatory status of pancreatic cancer cells as well as their stem cell properties.